Parsippany, New Jersey, September 21, 2026
Teva Pharmaceuticals has announced new real-world data for UZEDY® (risperidone) extended-release injectable suspension, highlighting treatment continuity, healthcare resource utilization and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I). The findings were presented at Psych Congress 2026, held September 15–19 in New Orleans, Louisiana. The new analyses evaluated UZEDY against other long-acting injectable antipsychotics and oral antipsychotic treatments, with findings focused on treatment adherence, treatment persistence, emergency department visits, hospitalizations and healthcare costs. Teva reported that the data showed favorable treatment continuity for UZEDY and reductions in healthcare resource utilization in several matched real-world comparisons.
Teva Presents Real-World UZEDY Data
The new evidence includes multiple analyses examining how UZEDY performs in routine clinical practice. In one matched cohort analysis involving 1,166 patients, researchers compared once-monthly UZEDY with once-monthly paliperidone palmitate in adults with schizophrenia. Teva reported that 22.0% of UZEDY-treated patients experienced an emergency department visit compared with 27.8% of those receiving paliperidone palmitate. The analysis also reported a 40% lower all-cause emergency department visit rate for the UZEDY group and numerically fewer inpatient hospitalizations.
The analysis also examined healthcare costs. Estimated mean monthly direct healthcare costs were reported as $4,688.10 for UZEDY compared with $5,724.80 for paliperidone palmitate, representing an adjusted mean monthly difference of $1,036.70 per patient. These findings provide information on healthcare resource utilization in a real-world population, although the observational, matched-cohort design means that the results should be interpreted as comparative real-world evidence rather than as findings from a randomized controlled trial.
UZEDY Data Examine Treatment Continuity
Advertisement
Additional matched-cohort analyses compared once-monthly UZEDY with other long-acting injectable antipsychotics, including risperidone microspheres administered every two weeks, once-monthly aripiprazole and once-monthly haloperidol decanoate. Teva reported the largest differences in treatment continuity when UZEDY was compared with risperidone microspheres. In that comparison, UZEDY-treated patients had 3.6 times higher odds of adherence and an 80% lower likelihood of discontinuation, according to the company’s analysis. The findings also included emergency-care and hospitalization outcomes. Teva reported lower emergency department visit rates for UZEDY compared with risperidone microspheres and haloperidol decanoate, while outcomes compared with once-monthly aripiprazole were generally comparable. These analyses are intended to provide additional information about how treatment choices may perform outside controlled clinical-trial environments.
Real-world evidence can complement randomized clinical-trial data by examining treatment patterns among patients receiving therapy in everyday healthcare settings. However, differences between treatment groups may reflect patient characteristics, prescribing patterns and other factors that cannot always be completely accounted for in observational analyses.
Teva Reports UZEDY Data in Bipolar I Disorder
Teva also presented new real-world evidence involving adults with bipolar I disorder who switched from oral antipsychotics to UZEDY or another oral antipsychotic. A retrospective chart review included 358 matched patients, with 179 patients in each treatment group. According to Teva, patients who switched to UZEDY experienced less treatment failure, reported at 47% compared with 63% among patients who switched to another oral antipsychotic. The analysis also reported that patients receiving UZEDY were more likely to remain on treatment without experiencing bipolar I disorder- or mania-related hospitalization, emergency department visits or discontinuation because of inadequate effectiveness. These findings add to the real-world evidence being presented for UZEDY across severe mental health conditions.
UZEDY (risperidone) is an extended-release injectable suspension administered subcutaneously and is approved for the treatment of schizophrenia in adults and for maintenance treatment of bipolar I disorder in adults, either as monotherapy or with lithium or valproate. Teva states that UZEDY is available in one-month and two-month dosing intervals and uses polymer technology licensed from Medincell for sustained drug release. For Teva, the latest findings add to the growing body of real-world evidence surrounding UZEDY and its potential role in long-term management of schizophrenia and bipolar I disorder. The data presented at Psych Congress 2026 focus not only on clinical treatment continuity but also on healthcare utilization and economic outcomes, providing additional information for researchers and healthcare professionals evaluating long-acting injectable treatment strategies.
Source: Teva press release
